EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

A systematic assessment of robustness in CNS safety pharmacology

Maria Reiber, Helen Stirling, Tim P Ahuis, Washington Arias, Katharina Aulehner, Ute Dreßler, Martien J H Kas iD, Johanna Kela, Kimberly Kerker, Tarja Kuosmanen, Helga Lorenz, Alexander T Pennington und 9 weitere

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17358 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Maria Reiber und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany. Hauptthemen laut MEDLINE: Dizocilpine Maleate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative 2 Joint Undertaking, German Research Foundation, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Irwin tests are key preclinical study elements for characterising drug‐induced neurological side effects. This multicentre study aimed to assess the robustness of Irwin tests across multinational sites during three stages of protocol harmonisation. The projects were part of the Enhanced Quality in Preclinical Data framework, aiming to increase success rates in transition from preclinical testing to clinical application. Experimental Approach Female and male NMRI mice were assigned to one of three groups (vehicle, MK‐801 0.1 and 0.3 mg kg −1 ). Irwin scores were assessed at baseline and multiple times following intraperitoneal injection of MK‐801 using local protocols (Stage 1), shared protocols with harmonised environmental design (Stage 2) and fully harmonised Irwin scoring protocols (Stage 3). Key Results The analysis based on the four functional domains (motor, autonomic, sedation and excitation) revealed substantial data variability in Stages 1 and 2. Although there was still marked overall heterogeneity between sites in Stage 3 after complete harmonisation of the Irwin scoring scheme, heterogeneity was only moderate within functional domains. When comparing treatment groups versus vehicle, we found large effect sizes in the motor domain and subtle to moderate effects in the excitation‐related and autonomic domains. Conclusion and Implications The pronounced interlaboratory variability in Irwin datasets for the CNS‐active compound MK‐801 needs to be carefully considered when making decisions during drug development. While environmental and general study design had a minor impact, the study suggests that harmonisation of parameters and their scoring can limit variability and increase robustness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dizocilpine MaleateAnimalsMiceMaleFemaleDrug Evaluation, PreclinicalCentral Nervous SystemCentral Nervous System Agents

Stichwörter der Autor:innen

adverse drug reactionmousemulticentremultilaboratoryreproducibilityresearch design

Substanzen

Dizocilpine MaleateCentral Nervous System Agents

Autor:innen und Institutionen

  • Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • PsychoGenics, Inc., Paramus, New Jersey, USA.
  • AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
  • Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands.
  • Orion Corporation, Turku, Finland.

ORCID-Profile: Martien J H Kas, Heidrun Potschka

Förderung

  • Innovative Medicines Initiative 2 Joint Undertaking
  • German Research Foundation
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Reiber, M., Stirling, H., Ahuis, T. P., Arias, W., Aulehner, K., Dreßler, U., Kas, M. J. H., Kela, J., Kerker, K., Kuosmanen, T., Lorenz, H., Pennington, A. T., von Rüden, E. L., Schauerte, H., Seiffert, I., Talbot, S. R., Torturo, C., Virtanen, S., Waldron, A. M., …, & Potschka, H. (2025). A systematic assessment of robustness in CNS safety pharmacology. British Journal of Pharmacology. https://doi.org/10.1111/bph.17358

Vancouver

Reiber M, Stirling H, Ahuis TP, Arias W, Aulehner K, Dreßler U, et al. A systematic assessment of robustness in CNS safety pharmacology. British Journal of Pharmacology. 2025. doi:10.1111/bph.17358

BibTeX
@article{Reiber2025,
  author = {Reiber, Maria and Stirling, Helen and Ahuis, Tim P and Arias, Washington and Aulehner, Katharina and Dreßler, Ute and Kas, Martien J H and Kela, Johanna and Kerker, Kimberly and Kuosmanen, Tarja and Lorenz, Helga and Pennington, Alexander T and von Rüden, Eva-Lotta and Schauerte, Heike and Seiffert, Isabel and Talbot, Steven R and Torturo, Christina and Virtanen, Sami and Waldron, Ann-Marie and Ramboz, Sylvie and Potschka, Heidrun},
  title = {A systematic assessment of robustness in CNS safety pharmacology},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17358}
}
Kostenlos starten →